Please assess the completion status of the following clinical trial:

Trial Title: Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for 6 months or greater~* Currently taking stable diabetes medication for 3 months or greater~* HbA1c between 7-10%~* LDL-cholesterol greater than 70 mg/dL~* Women must not be pregnant, lactating, or planning to become pregnant within 30 days after last dose of study medication; and must be postmenopausal, surgically sterile, or willing to use 1 acceptable form of birth control during the study through 30 days after the last dose of study medication~Exclusion Criteria:~* Body mass index \> 40 kg/m2~* History of documented clinically significant cardiovascular disease~* Fasting triglycerides \> 400 mg/dL~* History of Type 1 diabetes~* Uncontrolled hypothyroidism, liver dysfunction, renal dysfunction, gastrointestinal condition that may affect drug absorption, hematologic or coagulation disorder or active malignancy~* History of drug or alcohol abuse within 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bempedoic acid + Ezetimibe FDC (Type: EXPERIMENTAL): Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Oral Tablet, Placebo oral capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).